Dupilumab Induces Hair Regrowth in Pediatric Alopecia Areata: A Real-World, Single-Center Observational Study

This study evaluated the effectiveness of dupilumab in promoting hair regrowth in 20 pediatric patients with alopecia areata (AA) and atopic dermatitis (AD), aged 5-16 years. Over a follow-up period averaging 67.6 weeks, patients showed significant improvement in hair regrowth, as measured by the Severity of Alopecia Tool (SALT), with mean scores decreasing from 54.4 at baseline to 20.4 at 48 weeks and further to 2.2 beyond 72 weeks. The study found correlations between baseline SALT scores and disease duration, as well as between baseline IgE levels and improvement in SALT scores. Dupilumab was well-tolerated, with no new safety concerns, suggesting its potential as a safe treatment for pediatric AA, highlighting the need for larger clinical trials.